PDF Cover

Insulin Delivery Devices Market

The market for Insulin Delivery Devices was estimated at $36.6 billion in 2024; it is anticipated to increase to $57.7 billion by 2030, with projections indicating growth to around $84.4 billion by 2035.

Report ID:DS1801041
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Insulin Delivery Devices
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Insulin Delivery Devices Market Outlook

Revenue, 2024

$36.6B

Forecast, 2034

$78.3B

CAGR, 2025 - 2034

7.9%

The Insulin Delivery Devices industry revenue is expected to be around $39.5 billion in 2025 and expected to showcase growth with 7.9% CAGR between 2025 and 2034. The path shows why Insulin Delivery Devices hold critical value for worldwide diabetes treatment because healthcare organizations focus on developing exact and secure insulin delivery systems which provide users with better treatment results and enhanced life quality. The increasing number of 1 Diabetes and 2 Diabetes cases together with population aging and physical inactivity and increasing obesity rates creates an urgent need for sophisticated drug delivery systems which help patients control their condition while minimizing side effects from treatment. The landscape contains 1 Diabetes and 2 Diabete as the only indications which together make up 100.0% of the market share because these patients need dependable insulin treatment for their condition. The Pens Product generated $17.09 billion in revenue during 2024 because healthcare providers and patients chose these user friendly insulin pens because they offered both portability and precise dosing and easy operation. The market shift toward connected Insulin Delivery Devices which link with digital decision support tools has gained support from payers and providers because these devices help patients follow their treatment plans better while making healthcare resources more efficient and ensuring the market stays important in the future.

The portfolio of Insulin Delivery Devices includes multiple technologies which include disposable and reusable pens and conventional syringes and patch based systems and advanced insulin pumps that deliver controlled basal and bolus doses based on individualized treatment protocols. The system provides stable glycemic control for 1 Diabetes and 2 Diabete patients through its fine dose titration feature and ergonomic design and integrated safety mechanisms and continuous glucose monitoring system connectivity which operates in homecare and hospital and specialty clinic environments. The current focus of innovation centers on smart insulin pens which combine sensors with application based dose monitoring systems and analytical tools and small wearable insulin devices which offer unobtrusive continuous drug delivery and enable distant patient tracking through digital healthcare platforms. The combination of new technologies with patient focused design approaches and individualized medical treatments and diabetes management through technology has created new standards for Insulin Delivery Devices which now drive their market growth in established and developing countries.

Insulin Delivery Devices market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Insulin Delivery Devices Market Outlook

Market Key Insights

  • The Insulin Delivery Devices market will expand from $36.6 billion in 2024 to $78.2 billion during the period from 2024 to 2034. The market shows a 7.89% annual growth rate because customers increasingly need solutions for Diabetes Management and Emergency Hypoglycaemia Treatment and Pediatric Diabetes Care.

  • The market leaders Novo Nordisk A/S, Sanofi, Eli Lilly and Company determine the competitive dynamics of this industry.

  • The Insulin Delivery Devices market has U.S. and Germany as its leading markets which will experience CAGR growth of 5.1% to 7.6% during 2024 to 2030.

  • Our analysis predicts that China, India and Brazil will experience the most significant growth in emerging markets at rates between 9.1% and 10.9% CAGR.

  • The Insulin Delivery Devices market will experience $5 billion additional growth because of Transition like Digital Transformation in Insulin Delivery during the period from 2030 to 2030.

  • The Insulin Delivery Devices market will experience a $41.6 billion growth span from 2024 to 2034 while manufacturers focus on developing products for Clinics & Home Care Settings Application which will dominate market expansion.

  • The Insulin Delivery Devices market will experience a 114% growth from 2024 to 2034 because of advancing insulin delivery technology and rising diabetes cases.

insulin delivery devices market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Insulin Delivery Devices - Country Share Analysis

Opportunities in the Insulin Delivery Devices

Working professionals with 2 diabetes who live in Indias fast growing urban region's now choose insulin delivery devices which offer both ease of use and unobtrusive design and include reusable and prefilled insulin pens. The market for insulin pens will also expand from 17.09 billion dollars to 26.08 billion dollars during the period from 2025 to 2030 which enables manufacturers to create products that match local needs through ergonomic design and Hindi and regional language instructions and dose memory features for home healthcare and self administration. The pen focused segment will experience significant volume expansion through strategic alliances with corporate wellness programs and digital pharmacies.

Growth Opportunities in North America and Asia Pacific

The North American market for Insulin Delivery Devices receives its primary influence from 1 diabetes treatment which uses sophisticated insulin pumps and smart insulin delivery systems at high rates but 2 diabetes management requires insulin pens and diabetes management devices in high quantities; the market offers three main opportunities to enhance current users with wearable insulin devices that use data and to develop home healthcare systems with digital connections and to link medical records with tele endocrinology services. The market shows intense competition because multinational manufacturers who currently dominate the market use their service networks and relationships with healthcare providers to protect their position yet digital health startups with flexible operations use their connected platforms and user friendly interfaces and performance based solutions to challenge them. The main factors which drive the region forward include established payment systems for advanced Insulin Delivery Devices and medical standards which promote insulin treatment beginning at the first sign of need and increasing numbers of people developing diabetes and obesity while patients want products which combine ease of use with unobtrusive design to drive up sales of smart cloud based solutions which justify higher prices for unique product lines.
The Asia Pacific region bases its Insulin Delivery Devices market demand on 2 diabetes treatment because the region contains numerous diabetic patients who need insulin therapy but have not only received it yet. The region maintains its focus on 1 diabetes treatment through its urban tertiary care facilities which use advanced insulin pumps and smart pens for their patients. The market requires three main product categories which include affordable insulin pens and prefilled devices and wearable insulin devices and hybrid products that unite basic and smart features to serve patients from different economic backgrounds. The market competition has become more fierce because regional manufacturers now operate in the mid and value segments which forces global companies to establish local manufacturing facilities to win government contracts and maintain their market presence in smaller cities. Premium brands need to establish their market position through reliable products and clinical support services and digital health system integration because price competition no longer works as a differentiator. The main factors driving growth stem from fast urban development and higher medical diagnosis numbers and state supported programs for managing chronic diseases and better health insurance benefits for Insulin Delivery Devices and growing home healthcare services and pharmacy based care services.

Market Dynamics and Supply Chain

01

Driver: Growing Diabetes Prevalence and Rising Demand for Smart, Patient-Centric Delivery Solutions

The increasing global prevalence of diabetes, driven by aging populations, sedentary lifestyles, and rising obesity rates, is also a major growth factor for the insulin delivery devices market. As more individuals require insulin therapy, demand for accessible, user-friendly delivery systems rises across outpatient and home care settings. This trend is also especially strong in emerging economies where healthcare access is also improving. Alongside this, technological advancements in smart and connected delivery solutions are also transforming patient care. Integration of wireless connectivity, real-time monitoring, and app-based dose tracking enhances adherence and glycemic outcomes. Smart insulin pens and connected pumps that sync with continuous glucose monitors empower users with data-driven insights and personalized dosing alerts, improving quality of life and reducing complications. Combined, rising disease burden and innovation toward intelligent, patient-centric devices are also expanding adoption across age groups and care settings while encouraging investment from key medical device manufacturers.
Technological progress in automated insulin delivery and closed-loop systems is also a key driver of market expansion. These systems, which combine continuous glucose monitoring with algorithm-based insulin dosing, reduce manual input and help maintain tighter glycemic control. Improvements in predictive algorithms, sensor accuracy, and wearable hardware are also enhancing user experience and clinical outcomes. As a result, both patients and healthcare providers increasingly prefer these advanced solutions over traditional pens, boosting demand and encouraging further innovation from leading device companies.
02

Restraint: High Device Costs and Reimbursement Barriers Restrict Broader Adoption Worldwide

Insulin delivery devices like smart pens and automated pumps often carry high upfront and ongoing costs, limiting accessibility, especially in low-income regions. Insurers may not fully reimburse advanced systems, forcing patients to choose basic or manual options. For example, expensive closed-loop pumps have slower uptake where reimbursement is weak, reducing overall market revenue. This cost barrier dampens demand and slows adoption of premium technologies despite clinical benefits, particularly outside North America and Western Europe.
03

Opportunity: Expanding home-based diabetes management using affordable syringes and pen needles across underserved Latin American communities and Integration of smart insulin pumps with digital therapeutics for tech-savvy adolescents in North America

Traditional insulin syringes and pen needles serve as the main treatment tools for home based daily therapy among cost conscious patients who live in underprivileged Latin American region's. The global market for syringes will expand from 2.71 billion dollars to 3.53 billion dollars while pen needles will increase from 4.98 billion dollars to 8.03 billion dollars during the 2030 period because people need affordable devices to deliver insulin. The local manufacturing sector together with government tender opportunities and training programs run through primary care clinics will create more opportunities for safe self injection of pen needles which show the fastest growth in low cost options throughout the region.
North American adolescents who are technology oriented need diabetes management tools which combine smart insulin pumps with continuous glucose monitoring and mobile applications. The global market for insulin pumps shows the highest growth rate because it will expand from 9.95 billion dollars to 17.25 billion dollars during the 2030 period with a 9.6% annual growth rate. The differentiation of device makers becomes possible through their development of gamified adherence dashboards and their creation of interoperable APIs and their design of school compatible wearable insulin pump devices. The adoption of this advanced pump segment will gain speed through partnerships between digital therapeutics platforms and pediatric endocrinology networks.
04

Challenge: Persistent Technical Challenges and User Training Complexity Undermine Patient Confidence

Technical limitations such as sensor inaccuracies, infusion set failures, and complex operation reduce confidence in advanced insulin delivery systems. Users may experience interrupted therapy due to device errors or struggle with calibration and maintenance. For instance, frequent pump site issues can lead patients to revert to injections, lowering long-term device utilization. These usability and reliability concerns constrain market growth by increasing support costs and deterring potential adopters.

Supply Chain Landscape

1

Drug Delivery Components

Gerresheimer AGWest Pharmaceutical ServicesBecton Dickinson
2

Insulin Delivery Devices

Novo Nordisk A/SSanofiEli Lilly and Company
3

Medical Device Distribution

McKesson CorporationCardinal HealthAmerisourceBergen
4

Diabetes Care

HospitalsDiabetes clinicsHomecare settings
Insulin Delivery Devices - Supply Chain

Use Cases of Insulin Delivery Devices in Diabetes Management & Emergency Hypoglycaemia Treatment

Diabetes Management : Insulin delivery devices play a central role in ongoing diabetes management by enabling precise and consistent insulin administration for individuals with type 1 and insulin-dependent type 2 diabetes. Devices such as ClickOnCare HumaPen Ergo 2 and Humapen Ergo II - Penfill Device deliver accurate dosing while supporting patient adherence and glycemic control. Insulin pens are widely used due to their ease of use, portability, and dose accuracy, capturing a substantial share of the market, especially in outpatient and home settings. Insulin pumps and automated insulin delivery systems further enhance management by providing basal and bolus dosing tailored to glucose trends, improving quality of life and clinical outcomes. Medtronic, Tandem Diabetes Care, Insulet, Novo Nordisk, and Eli Lilly rank among the leading providers innovating across pump and smart pen technologies to meet diverse patient needs.
Emergency Hypoglycaemia Treatment : In emergency hypoglycemia situations, rapid glucose elevation is critical to prevent serious complications, and specialized delivery devices are essential. While traditional glucagon rescue kits remain a cornerstone for emergency treatment, integration with insulin delivery systems or connected alerts from continuous glucose monitors linked to pumps can help patients anticipate and respond to dangerously low blood sugar. Glucagon rescue kits manufactured by Novo Nordisk and Eli Lilly allow caregivers or patients to administer lifesaving treatment quickly when consciousness is impaired, reducing the need for hospital intervention. This application underscores the importance of seamless care pathways between everyday insulin delivery and emergency response tools for high-risk patients.
Pediatric Diabetes Care : Pediatric diabetes care demands adaptable, child-friendly insulin delivery solutions that support growth, activity, and variable daily routines. Insulin pens and pumps calibrated for pediatric dosing help children maintain tighter glucose control with minimal discomfort. Patch-style and tubeless pumps are growing in appeal among younger users for their discreet, wearable profiles and reduced needle anxiety, improving adherence and quality of life. Leading companies such as Medtronic, Insulet, Roche, and Tandem Diabetes Care are advancing platforms that integrate insulin delivery with continuous glucose data and predictive dosing algorithms, tailoring therapy to the unique needs of pediatric patients. Enhanced safety features and easy usability make these devices especially valuable in school, travel, and everyday care environments.

Recent Developments

Insulin delivery devices are rapidly evolving with non-invasive technologies like inhalable insulin and wearable insulin patches gaining traction alongside smart pens and automated insulin pumps. A key market trend is integration with continuous glucose monitoring and digital health platforms, improving dose accuracy and patient adherence. Manufacturers are focusing on personalized diabetes care, connected health, and sensor-based feedback to enhance outcomes. Strategic partnerships and innovation in drug-device combinations are expanding access and driving competitive differentiation in the diabetes management space.

January 2025 : Novo Nordisk A/S expanded its insulin delivery portfolio by launching Awiqli (insulin icodec injection) in Japan using its prefilled FlexTouch delivery device, enhancing patient convenience with once-weekly dosing.
September 2025 : Medtronic’s MiniMed 780G automated insulin pump received U.S. FDA approval with enhanced smartphone app control, improving usability and real-time diabetes management.
August 2024 : Insulet announced CE Mark approval under EU regulations for the Abbott FreeStyle Libre sensor to integrate with its Omnipod 5, expanding interoperable insulin delivery options.

Impact of Industry Transitions on the Insulin Delivery Devices Market

As a core segment of the Medical Device industry, the Insulin Delivery Devices market develops in line with broader industry shifts. Over recent years, transitions such as Digital Transformation in Insulin Delivery and Transitioning to Non-invasive Insulin Delivery Methods have redefined priorities across the Medical Device sector, influencing how the Insulin Delivery Devices market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Digital Transformation in Insulin Delivery

The market transition from hardware based products to data enabled diabetes management solutions will occur because Insulin Delivery Devices are undergoing fast digital transformation through AI and IoT integration which will create a $5 billion market expansion by 2030. Smart insulin pens and connected insulin pumps now link with mobile health apps and continuous glucose monitoring systems to provide real time personalized dosing and enhance therapy adherence. The system enables remote patient monitoring and cloud based analytics which generates new value streams through its connection of devices and software and service platforms. The market shift toward digital insulin delivery systems which show better glycemic control and user satisfaction will benefit manufacturers who develop AI based glucose monitoring systems and platform solutions which operate across different systems.
02

Transitioning to Non-invasive Insulin Delivery Methods

The transition toward non-invasive insulin delivery methods is reshaping the insulin delivery devices market by reducing dependence on traditional injections. Innovations such as insulin patches, microneedle systems, and inhalable insulin improve patient comfort, adherence, and long-term therapy acceptance. For example, wearable insulin patches enable discreet, needle-free dosing, increasing uptake among elderly and needle-averse patients. Inhaled insulin has also influenced respiratory device manufacturers and pharmaceutical formulation specialists, driving cross-industry collaboration. This shift impacts digital health, as non-invasive systems increasingly integrate sensors and mobile apps for dose monitoring. Additionally, reduced reliance on syringes affects the disposable medical supplies market. Overall, the move toward painless delivery is expanding the addressable patient base, encouraging product differentiation, and accelerating innovation across connected healthcare and drug-device combination industries.